COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR FOR THE TREATMENT OF TREATMENT-NAIVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS IN GERMANY

被引：0
|
作者：
Stahmeyer, J. T. [1 ]
Schauer, S. [1 ]
Wirth, D. [2 ]
Fleischmann, J. [3 ]
Lee, S. [4 ]
Gavart, S. [5 ]
Bianic, F. [6 ]
Cure, S. [7 ]
Krauth, C. [1 ]
机构：
[1] Hannover Med Sch, D-3000 Hannover, Germany
[2] Janssen Cilag GmbH, Neuss, Germany
[3] Janssen Cilag Germany, Neuss, Germany
[4] Co Johnson & Johnson, Janssen Global Serv, Horsham, PA USA
[5] Janssen Pharmaceut, B-2340 Beerse, Belgium
[6] OptumInsight, Nanterre, France
[7] OptumInsight, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1129
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A396 / A396
页数：1
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF TELAPREVIR TRIPLE THERAPY IN TREATMENT OF NAIVE CHRONIC HEPATITIS C PATIENTS IN TURKEY
    Ozdemir, O.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A670 - A670
  • [2] Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options
    Cortesi, P. A.
    Ciaccio, A.
    Rota, M.
    Lim, J. K.
    De Salvia, S.
    Okolicsanyi, S.
    Vinci, M.
    Belli, L. S.
    Mantovani, L. G.
    Strazzabosco, M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 (02) : 175 - 183
  • [3] Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients
    Blazquez-Perez, Antonio
    San Miguel, Ramon
    Mar, Javier
    [J]. PHARMACOECONOMICS, 2013, 31 (10) : 919 - 931
  • [4] Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients
    Antonio Blázquez-Pérez
    Ramón San Miguel
    Javier Mar
    [J]. PharmacoEconomics, 2013, 31 : 919 - 931
  • [5] Cost-effectiveness analysis of telaprevir triple therapy for treatment-naive patients with chronic hepatitis C based on the combined efficacy data of the ADVANCE and OPTIMIZE studies
    Buti, Maria
    Gros, Blanca
    Oyagueez, Itziar
    Andrade, Raul J.
    Angel Serra, Miguel
    Turnes, Juan
    Casado, Miguel A.
    [J]. HEPATOLOGY, 2013, 58 : 1133A - 1133A
  • [6] COST-EFFECTIVENESS OF TELAPREVIR COMBINATION THERAPY COMPARED TO PEGINTERFERON WITH RIBAVIRIN ALONE FOR NAIVE AND TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN POLAND
    Kaczor, M. P.
    Wojcik, R.
    Pawlik, D.
    Skrzekowska-Baran, I
    Tronczynski, K.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A359 - A360
  • [7] THE COST-EFFECTIVENESS OF HEPATITIS C TREATMENTS IN TREATMENT NAIVE GENOTYPE 1 PATIENTS
    McGinnis, J. J.
    Hay, J. W.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A274 - A274
  • [8] Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China
    Lu, Yun
    Jin, Xiuze
    Duan, Cheng-a-xin
    Chang, Feng
    [J]. PLOS ONE, 2018, 13 (04):
  • [9] Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naive chronic hepatitis C genotype 1 patients in Japan
    Kuwabara, Hiroyo
    Westerhout, Kirsten
    Treur, Maarten
    Cerri, Karin
    Mahlich, Joerg
    Yatsuhashi, Hiroshi
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (07) : 502 - 511
  • [10] COST-EFFECTIVENESS OF TELAPREVIR WITH PEGINTERFERON AND RIBAVIRIN FOR TREATMENT-NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV OF GENOTYPE 1 IN JAPAN
    Ishida, H.
    Terai, S.
    Sakaida, I
    Inoue, Y.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A328 - A328
12345